Patents by Inventor Le Cong
Le Cong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240051498Abstract: A control apparatus and a method for locking or unlocking a door include a smart key including a door locking and unlocking button provided thereon and configured for transmitting a control signal for locking or unlocking the door through a door locking and unlocking button; a smart key check module configured to determine whether the smart key is in a vehicle; and a door control module configured to determine whether the vehicle is in a started state or a turned-off state, determine whether to receive a control signal for locking or unlocking the door from the smart key according to a result of the determining whether the smart key is in the vehicle when the vehicle is in the started state, and control a corresponding door of the vehicle when receiving the control signal for locking or unlocking the door from the smart key.Type: ApplicationFiled: February 13, 2023Publication date: February 15, 2024Applicants: Hyundai Motor Company, Kia CorporationInventors: Bing Le CONG, Jing Song Sun, Xu Qiang Sun
-
Publication number: 20230287373Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRJSPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CR.ISPR-Cas enzyme systems. In particular the present invention comprehends engineered new guide architectures and enzymes to be used in optimized Staphylococcus aureus CRISPR-Cas enzyme systems.Type: ApplicationFiled: January 26, 2023Publication date: September 14, 2023Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, University of TokyoInventors: Feng ZHANG, Winston YAN, Osamu NUREKI, Kaijie ZHENG, Le CONG, Hiroshi NISHIMASU, Fei RAN, Yinqing LI
-
Publication number: 20230091242Abstract: The present disclosure provides recombineering-editing systems using CRISPR and recombination enzymes as well as methods, vectors, nucleic acid compositions, and kits thereof. The methods and systems provide means for altering target DNA, including genomic DNA in a host cell.Type: ApplicationFiled: March 2, 2021Publication date: March 23, 2023Inventor: Le Cong
-
Patent number: 11578312Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems. In particular the present invention comprehends engineered new guide architectures and enzymes to be used in optimized Staphylococcus aureus CRISPR-Cas enzyme systems.Type: GrantFiled: December 12, 2017Date of Patent: February 14, 2023Assignees: THE BROAD INSTITUTE INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, UNIVERSITY OF TOKYOInventors: Feng Zhang, Winston Yan, Osamu Nureki, Kaijie Zheng, Le Cong, Hiroshi Nishimasu, Fei Ran, Yinqing Li
-
Publication number: 20230029506Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.Type: ApplicationFiled: June 3, 2022Publication date: February 2, 2023Applicants: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Le CONG, David Benjamin Turitz COX, Matthias HEIDENREICH, Randall Jeffrey PLATT, Lukasz SWIECH, Feng ZHANG
-
Patent number: 11434262Abstract: Provided herein are compositions, kits and methods useful in the construction of designer transcription activator-like effector (dTALE) polypeptides.Type: GrantFiled: October 26, 2016Date of Patent: September 6, 2022Assignee: President and Fellows of Harvard CollegeInventors: Feng Zhang, Le Cong, Sriram Kosuri, George M. Church
-
Patent number: 11407985Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.Type: GrantFiled: June 10, 2016Date of Patent: August 9, 2022Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Le Cong, David Benjamin Turitz Cox, Matthias Heidenreich, Randall Jeffrey Platt, Lukasz Swiech, Feng Zhang
-
Publication number: 20220204954Abstract: The disclosure provides variant Staphylococcus aureus Cas9 (SaCas9) proteins with altered specificity for protospacer adjacent motif (PAM) sequences. The disclosure also is directed to CRISPR/Cas9 systems and methods of altering a genomic DNA sequence using the variant SaCas9 protein. Methods of generating variant Cas9 proteins with altered PAM specificity are also disclosed.Type: ApplicationFiled: April 24, 2020Publication date: June 30, 2022Inventor: Le Cong
-
Patent number: 11332719Abstract: The present invention generally relates to methods and compositions used delivery of gene editing compositions including transcriptional effectors with parvovirus and preferred methods for making same.Type: GrantFiled: March 14, 2014Date of Patent: May 17, 2022Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Feng Zhang, Mark D. Brigham, Le Cong, Silvana Konermann
-
Patent number: 11312937Abstract: The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.Type: GrantFiled: June 19, 2018Date of Patent: April 26, 2022Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Feng Zhang, Le Cong
-
Patent number: 11214797Abstract: The present invention provides tools and methods for the systematic analysis of genetic interactions, including higher order interactions. The present invention provides tools and methods for combinatorial probing of cellular circuits, for dissecting cellular circuitry, for delineating molecular pathways, and/or for identifying relevant targets for therapeutics development.Type: GrantFiled: April 27, 2018Date of Patent: January 4, 2022Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Regents of the University of CaliforniaInventors: Aviv Regev, Brittany Adamson, Brian Cleary, Le Cong, Atray Dixit, Jellert Gaublomme, Eric S. Lander, Thomas Norman, Oren Parnas, Orit Rozenblatt-Rosen, Alexander K. Shalek, Jonathan Weissman
-
Publication number: 20210403861Abstract: The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.Type: ApplicationFiled: September 16, 2021Publication date: December 30, 2021Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Feng ZHANG, Le Cong
-
Patent number: 11186825Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.Type: GrantFiled: April 30, 2018Date of Patent: November 30, 2021Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
-
Publication number: 20210361779Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.Type: ApplicationFiled: March 15, 2021Publication date: November 25, 2021Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Feng Zhang, Le Cong, Fei Ran, Matthias Heidenreich, Lukasz Swiech
-
Patent number: 11180730Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.Type: GrantFiled: April 30, 2018Date of Patent: November 23, 2021Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
-
Patent number: 11036670Abstract: A electronic device includes a USB Type-C interface, a switching circuit, a first signal path, and a second signal path. The USB Type-C interface is configured to connect to a USB Type-C device. The switching circuit is connected to the USB Type-C interface, the first signal path, and the second signal path. When the USB Type-C interface is connected to the USB Type-C device, the first signal path is connected to the USB Type-C interface through the switching circuit, and a level of a first pin of the USB Type-C interface is a first level. When the USB Type-C interface is disconnected from the USB Type-C device, the second signal path is connected to the USB Type-C interface through the switching circuit, and a level of the first pin is a second level. The first level is greater than the second level.Type: GrantFiled: October 31, 2017Date of Patent: June 15, 2021Assignee: HUAWEI TECHNOLGIES CO., LTD.Inventors: Junjie Li, Le Cong, Hongjun Zhao, Xuan Dai
-
Patent number: 10946108Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.Type: GrantFiled: December 16, 2015Date of Patent: March 16, 2021Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HAVARD COLLEGEInventors: Feng Zhang, Le Cong, Fei Ran, Matthias Heidenreich, Lukasz Swiech
-
Publication number: 20200392541Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues of organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provide dare methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.Type: ApplicationFiled: February 25, 2020Publication date: December 17, 2020Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Feng ZHANG, Le Cong, Fei Ran
-
Publication number: 20200354742Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: ApplicationFiled: July 24, 2020Publication date: November 12, 2020Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Feng ZHANG, Le Cong, Fei Ran
-
Patent number: 10801017Abstract: The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.Type: GrantFiled: May 30, 2014Date of Patent: October 13, 2020Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Feng Zhang, Le Cong, Sam Locascio